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Abstract
Background: Rectal leiomyosarcoma (LMS) is an extremely rare disease. Previously, LMS was not properly
distinguishable from gastrointestinal stromal tumor (GIST) until c-kit, a characteristic marker of GIST, was discovered
in 1998. No standard therapeutic strategy for gastrointestinal LMS has been established except for surgical resection
because of its rarity. Rectal LMS is often accompanied by symptoms, which can enable detection at a small size.
However, when a large LMS is detected at the lower rectum, it is difficult to excise due to the narrow pelvic space.
Case presentation: We present the case of an 86-year-old man with a large LMS. The LMS was asymptomatic
and incidentally found at the lower rectum when he visited another hospital for management of benign prostatic
hypertrophy. An abdominoperineal resection of the rectum was performed with combined resection of both
seminal vesicles and a part of the prostate because tumor invasion was suspected. We used the hybrid method
of laparoscopic and transanal total mesorectal excision (TaTME) approaches to achieve negative surgical margins.
Late-onset urethral injury occurred in the postoperative course, which was successfully treated with a urethral
catheter. The patient was discharged and received no adjuvant therapy. Local recurrence did not occur, but
multiple lung metastases were detected 4 months later and the patient died 12 months after the surgery.
Conclusions: This is the first report of the hybrid method of laparoscopic and TaTME approaches to remove a large
LMS at the lower rectum.
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Background
Gastrointestinal leiomyosarcoma (LMS) is a rare entity
that could not be accurately diagnosed until c-kit, a
characteristic marker of gastrointestinal stromal tumor
(GIST), was discovered in 1998 [1]. Rectal LMS is usu-
ally detected at a smaller size compared with colonic
LMS because there are often symptoms in rectal LMS
[2]. However, when a large tumor is found in the lower
rectum, it is difficult to excise because of the narrow pel-
vic space. Transanal total mesorectal excision (TaTME)
has been reported to be useful for removal of large pel-
vic tumors [3, 4]. Here, we present a case of large LMS
in the lower rectum. The cavity of the lesser pelvis was
almost completely occupied by the tumor. There has
been no report about a large LMS in the lower rectum
which was removed by the hybrid method of laparo-
scopic and TaTME approaches.
Case presentation
The patient was an 87-year-old man who had regularly
visited another hospital for management of benign pros-
tatic hyperplasia. His medical history included hyperten-
sion. In November 2013, a rectal mass was incidentally
identified. Colonoscopy showed a large submucosal
tumor at the lower rectum (Fig. 1). Pathological findings
from biopsy specimen showed spindle cells arranged in
irregular bands. Mitotic count was 3 per 10 high-power
fields, and there was no tumor necrosis. Immunohisto-
chemical staining for h-caldesmon, alfa-SMA, and
desmin was positive, while staining for DOG-1, CD117
(c-kit), CD34, and S-100 was negative. Ki-67 index was
40%. The rectal mass was diagnosed as a rectal LMS.
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The tumor was very large and considered difficult to be
removed by surgical intervention in that hospital. How-
ever, there were no other effective therapies except for
surgical resection. In January 2014, he was therefore re-
ferred to our hospital for surgical treatment.
Digital rectal examination revealed a large mass at the
anterior wall of the lower rectum, and the inferior edge
of the tumor was located 2 cm from the anal verge. La-
boratory findings were within normal ranges. Contrast-
enhanced computed tomography (CT) showed that the
size of the tumor was 7.5 cm in diameter and that there
were no signs of distant metastasis (Fig. 2). Abdominal
magnetic resonance imaging (MRI) showed that the
tumor originated from the anterior wall of the lower
rectum and that it was suspected to have invaded the left
seminal vesicle and prostate (Fig. 3). The tumor was close
to the urinary bladder, but a cystoscope showed no signs of
tumor invasion. 18F-fluorodeoxyglucose positron-emission
tomography showed no distant metastasis.
We made a diagnosis of a rectal LMS with suspected
invasion of the left seminal vesicle and prostate. In
March 2014, we performed an abdominoperineal
resection of the rectum combined with both seminal
vesicles and part of the prostate. We used the hybrid
method of laparoscopic and TaTME approaches for
better surgical view because it was apparently diffi-
cult to achieve negative surgical margins due to the
large tumor located within a narrow pelvic space
(Fig. 4). In this method, we used five trocars for lap-
aroscopic surgery and a multiple access port for
TaTME. A 12-mm trocar was inserted through an
umbilical incision, and then the pneumoperitoneum
was created. Another 12-mm trocar was placed in
the right lower abdominal region, and three 5-mm
trocars were inserted in the left lower abdominal
and bilateral lateral regions. Pathological findings
from the resected specimen showed that the tumor
was a pleomorphic LMS and that tumor cells had
invaded the left seminal vesicle and prostate with
negative surgical margin. No lymph node metastasis
was found. Immunohistochemical staining for calpo-
nin, alfa-SMA, and desmin was positive, while stain-
ing for DOG-1, c-kit, CD34, and S-100 was negative
(Fig. 5). Tumor necrosis was found in the surgical
specimen. The LMS was classified as grade 2 in
Federation Nationale des Centres de Lutte le Cancer
(FNCLCC) grading and stage IIb in TNM
classification. In the postoperative course, the patient
suffered from dysuria and needed intermittent self-
catheterization. Late-onset urethral injury occurred
30 days after the operation, which was successfully
treated with a urethral catheter. The patient was dis-
charged 42 days after the operation. The patient re-
ceived no adjuvant therapies such as chemotherapy
and radiotherapy. Four months later, multiple lung
metastases were detected on CT, although local re-
currence was not found. The patient died 12 months
after the operation.
Fig. 1 Endoscopic findings: colonoscopy revealed a large
submucosal tumor at the lower rectum. T tumor
Fig. 2 Contrast-enhanced computed tomography: a horizontal and b coronal sections. A large circle mass, 7.5 cm in diameter, was detected at
the lower rectum. It occupied almost all space of the lesser pelvis. P prostate, T tumor
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Discussion
It had been difficult to distinguish gastrointestinal
LMS from GIST until c-kit was discovered in 1998
[1]. That is, the previously diagnosed gastrointestinal
LMS is considered to include what is currently
termed GIST [5]. According to the recent literature,
the incidence of LMS was reported to be 1/50 to 1/
65 of the incidence of GIST [2, 5]. LMS originates
from smooth muscle cells and can arise anywhere in
human body, although the main locations of LMS are
the retroperitoneum, lower extremities, and the uterus
[6]. Therefore, gastrointestinal LMS is very rare and
its characteristics are still unclear.
To our knowledge, there are only 10 cases, including
our case, in the English-language literature since 1998 in
which immunohistochemical findings have been re-
ported [2, 5, 7] (Table 1). The patients were three men
and seven women. Median age was 65 years, ranging
from 24 to 88. Average tumor size was 3.8 cm. Polypect-
omy was performed in two cases, anterior resection in
three cases, abdominoperineal resection in four cases,
and the surgical method was not reported in one case.
Fig. 3 Magnetic resonance imaging T2-weighted images: Tumor invasion of the a left seminal vesicle and b prostate was suspected. LS left
seminal vesicle, P prostate, R rectum, T tumor
Fig. 4 Intraoperative views: a, b Laparoscopic views and c–e transanal total mesorectal excision view. AC abdominal cavity, LD left seminal vesicle
duct, LSV left seminal vesicle, P prostate, R rectum, RD right seminal vesicle duct, RP resected part of the prostate, RSV right seminal vesicle
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Common characteristics of three recurrent cases were
non-polypoid appearances such as Borrmann type 2-
and plaque-like lesions. Our case had the largest tumor
size, and there has been no report in which a large LMS
in the lower rectum was removed by the hybrid method
of laparoscopic and TaTME approaches.
FNCLCC grading includes three factors; tumor differ-
entiation, mitotic count, and tumor necrosis [8]. The
Union for International Cancer Control/the American
Joint Committee on Cancer staging system for soft tissue
sarcoma assesses the following factors; tumor size,
tumor depth, lymph node metastasis, distant metastasis,
and histological grade [9]. However, the characteristics
of gastrointestinal LMS have not been fully clarified be-
cause of its rarity [6]. Yamamoto et al. [5] reported that
tumor-specific overall survival rate was 51.6% and that
tumor size (≥5 cm) was significantly associated with a
poor prognosis. They also suggested that tumor depth
and necrotic area might be associated with patient sur-
vival. In our case, tumor size and gross appearance could
be associated with a poor prognosis, while mitotic count
was not. We surmised that patients with at least one risk
factor might have a poor prognosis.
There has been no standard therapeutic strategy for
gastrointestinal LMS. The effect of chemotherapy or
radiotherapy is still unclear, whereas some antitumor
drugs such as doxorubicin, ifosfamide, and eribulin are
suggested to be effective for soft tissue sarcomas [10–
12]. Surgical resection plays a critical role in the treat-
ment for gastrointestinal LMS [6]. Despite the fact that
lymph node metastasis is uncommon in soft tissue sar-
coma, lymph node dissection seems to be necessary for
gastrointestinal LMS because lymph node metastasis has
been reported [5].
Fig. 5 Surgical specimen and microscopic findings: a submucosal tumor at the lower rectum. b Hematoxylin-eosin stain (*20) revealed that spin-
dle cells were arranged in irregular bands. Immunohistochemical staining was positive for calponin (c) and alfa-SMA (d), and negative for c-kit (e)
Table 1 Reported cases of rectal leiomyosarcoma




2001 Miettinen et al. 63 F 2.0 Intraluminal polyp 68 – Alive 191
32 F 2.3 Intraluminal polyp >100 – Alive 39
79 F 2.5 Intraluminal polyp 26 – Death from OD 55
67 F 3.0 Plaque-like >100 Peritoneum Death from OD 61
52 M 3.0 Intramural 46 – Death from OD 70
40 M 3.5 Intraluminal polyp 45 – Alive 325
24 F 5.5 Intraluminal polyp 62 – NR NR
73 F NR NR >100 – Death from LMS 24
2013 Yamamoto et al. 88 F 6.5 Borrmann type 2-like 38 Skin, liver, peritoneum Death from LMS 24
2016 Our case 87 M 7.5 Submucosal tumor 15 Lung Death from LMS 12
F female, HPF high-power fields, LMS leiomyosarcoma, M male, NR not reported, OD other diseases
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In our case, we performed abdominoperineal resection
using the hybrid method of laparoscopic and TaTME ap-
proaches. It was considered difficult that the elderly pa-
tient underwent a total pelvic exenteration surgery and
took care of a urostomy together with a colostomy. We
assume that the TaTME approach is useful for the resec-
tion of a large pelvic tumor. Surgical margins were
negative for tumor cells by this approach, but it was very
close (<1 mm). There have been some reports on the
effectiveness of radiotherapy against local recurrence [6,
13, 14], while radiotherapy was reported to be a risk fac-
tor for LMS [15]. Adjuvant radiotherapy or chemother-
apy was not performed because there is no established
adjuvant therapy for rectal LMS and the elderly patient
did not hope to receive adjuvant therapies. However,
local recurrence was not found irrespective of the short
surgical margins. The late-onset urethral injury occurred
after surgery. We conceived that the self-catheterization
might make a negative impact on the occurrence. Four
months after the surgery, multiple lung metastases were
found. There have been some reports on the efficacy of
chemotherapy in other LMS cases [6, 10, 12, 16, 17]. It
also might prevent the recurrence of rectal LMS and
contribute to prolong patient survival.
Conclusions
We reported a case of LMS in the lower rectum. It was
successfully removed by the hybrid method of laparo-
scopic and TaTME approaches. This method can be use-
ful to achieve negative surgical margins in the resection
of large pelvic tumors.
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